|
MYL's Revenue Growth by Quarter and Year
Mylan N V 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| MYL Revenue (in millions $) |
FY 2020 |
FY 2019 |
FY 2018 |
FY 2017 |
| IV Quarter |
December |
-
|
8,538.80
|
3,078.70
|
3,144.00
|
| III Quarter |
September |
2,972.10
|
2,961.70
|
2,862.40
|
2,987.10
|
| II Quarter |
June |
2,731.20
|
-
|
2,808.30
|
2,719.50
|
| I Quarter |
March |
2,619.20
|
-
|
2,684.50
|
3,267.80
|
| FY |
|
8,322.50
|
11,500.50
|
11,433.90
|
12,118.40
|
| MYL Revenue third quarter 2020 Y/Y Growth Comment |
Mylan N v reported Revenue growth of 0.35% year on year in the third quarter 2020, to $ 2,972.10 millions, this is lower than Mylan N V 's recent average Revenue growth of 5.84%.
Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 108 other companies have achieved higher Revenue growth. While Mylan N V ' s Revenue increase of 0.35% ranks overall at the positon no. 1943 in the third quarter 2020.
|
| MYL Revenue ( Y/Y Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
- |
177.35 % |
-2.08 % |
2.84 % |
| III Quarter |
September |
0.35 % |
3.47 % |
-4.17 % |
16.65 % |
| II Quarter |
June |
- |
- |
3.27 % |
24.1 % |
| I Quarter |
March |
- |
- |
-17.85 % |
31.2 % |
| FY |
|
- |
0.58 % |
-5.65 % |
17.66 % |
MYL Revenue (Quarter on Quarter Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
- |
188.31 % |
7.56 % |
5.25 % |
| III Quarter |
September |
8.82 % |
- |
1.93 % |
9.84 % |
| II Quarter |
June |
4.28 % |
- |
4.61 % |
-16.78 % |
| I Quarter |
March |
-69.33 % |
- |
-14.62 % |
6.89 % |
| FY (Year on Year) |
|
- |
0.58 % |
-5.65 % |
17.66 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 76.01 % |
5.84 % |
-7.36 % |
| (Dec. 30, 2013) |
|
(Sep. 30, 2009) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 76.01 % |
5.84 % |
-7.36 % |
| (Dec. 30, 2013) |
|
(Sep. 30, 2009) |
|
| Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020 |
Mylan N V 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 188.31 % |
5.18 % |
-100 % |
| (Dec 31 2019) |
|
(Mar 31 2019) |
| MYL's III. Quarter Q/Q Revenue Comment |
Mylan N v achieved in the III. Quarter 2020 above company average sequential Revenue increase of 8.82%, to $ 2,972.10 millions, from $2,731.20 millions in the second quarter.
Mylan N V is going from strength to strength, with reporting better then normal growth, and additionally increasing pace, Angélica Almeida, market consultant said.
Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Mylan N V 's Revenue growth quarter on quarter, overall rank is 2106. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 188.31 % |
5.18 % |
-100 % |
| (Dec 31 2019) |
|
(Mar 31 2019) |
| MYL's III. Quarter Q/Q Revenue Comment |
Mylan N v achieved in the III. Quarter 2020 above company average sequential Revenue increase of 8.82%, to $ 2,972.10 millions, from $2,731.20 millions in the second quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, not just claiming higher then regular growth, and additionally increasing rate, Angélica Almeida, market consultant added.
Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Mylan N V 's Revenue growth quarter on quarter, overall rank is 2106. |
|
Mylan N V 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
12 Months Ending
(Dec 31 2019) |
12 Months Ending
(Sep 30 2019) |
| Cumulative Revenue 12 Months Ending |
$ 16,861.30 |
$ 16,850.90 |
$ 0.00 |
$ 0.00 |
$ 0.00 |
| Y / Y Revenue Growth (TTM) |
- |
- |
- |
- |
- |
| Year on Year Revenue Growth Overall
Ranking |
# |
# |
# |
# |
# |
| Seqeuential Revenue Change (TTM) |
0.06 % |
- |
- |
- |
- |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 1944 |
# 1945 |
# 0 |
# 0 |
# 0 |
| Cumulative Revenue growth
Comment |
Although Mylan N V 's Annual Revenue growth year on year were below company's average 20.04% , Revenue announced in the Sep 30 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.35% year on year, from % in Jun 30 2020. And, Mylan N V had the highest Revenue growth, in Major Pharmaceutical Preparations industry.
Mylan N v achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. . |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
76.01 % |
5.84 % |
-7.36 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
166.14 % |
20.04 % |
-34.88 % |
| (Sep. 30, 2008) |
|
(Mar 31 2019) |
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 109 |
| Sector |
# 343 |
| S&P 500 |
# 1944 |
|
| Cumulative Revenue growth
Comment |
Although Mylan N V 's Annual Revenue growth year on year were below company's average 20.04% , Revenue announced in the Sep 30 2020 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.35% year on year, from % in Jun 30 2020. And, Mylan N V had the highest Revenue growth, in Major Pharmaceutical Preparations industry.
Mylan N v achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. . |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
76.01 % |
5.84 % |
-7.36 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
166.14 % |
20.04 % |
-34.88 % |
| (Sep. 30, 2008) |
|
(Mar 31 2019) |
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 109 |
| Sector |
# 343 |
| S&P 500 |
# 1944 |
|
0.61%